Q&A: Page 2

Exclusive interviews with industry leaders

  • Jeremy Levin, CEO and chairman, Ovid Therapeutics
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip

    Red Jacket: Dr. Jeremy Levin, a transformational leader

    A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.

    Michael Gibney • Oct. 27, 2023
  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    Meagan Parrish • Oct. 27, 2023
  • Ken Getz, professor and executive director, Tufts Center for the Study of Drug Development
    Image attribution tooltip

    Industry Dive; Getty Images

    Image attribution tooltip

    Red Jacket: Ken Getz, a champion of clinical trials

    Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.

    Alexandra Pecci • Oct. 27, 2023
  • Adele Gulfo Red Jacket header
    Image attribution tooltip
    Permission granted by Sumitomo Pharma America
    Image attribution tooltip

    Red Jacket: Adele Gulfo, a commercialization guru

    With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.

    Karissa Waddick • Oct. 27, 2023
  • Actor and epilepsy advocate Greg Grunberg
    Image attribution tooltip
    Permission granted by Greg Grunberg
    Image attribution tooltip

    Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’

    The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.

    Michael Gibney • Oct. 19, 2023
  • pediatric cancer concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    To close the pediatric innovation gap, this biotech has to think differently

    Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

    Alexandra Pecci • Oct. 11, 2023
  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip

    5 minutes with — IDEA Pharma’s Mike Rea

    The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

    Meagan Parrish • Oct. 11, 2023
  • Jynneos Bavarian Nordic vaccine monkeypox
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    Inside Bavarian Nordic’s late-stage stumbles — and drive to become a vaccine giant

    Despite recent phase 3 setbacks in RSV and COVID-19, CEO Paul Chaplin sees a promising path forward in the travel vaccine market for the Danish biotech.

    Karissa Waddick • Sept. 27, 2023
  • Growing plant in low poly wireframe style
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Why Senda’s new chief medical officer says targeted delivery tech is like ‘science fiction’

    The Flagship-backed biotech believes the secret to more precise drug delivery lies in the nanoparticles of plants and fungi.

    Alexandra Pecci • Sept. 26, 2023
  • Opioids, pills, syringe
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As the opioid crisis seethes, a long-lasting treatment could offer new ammunition

    Launched this month, Brixadi from Braeburn gives patients a new tool to overcome addiction.

    Michael Gibney • Sept. 21, 2023
  • Close up of a machine with several tubes, some of which are red.
    Image attribution tooltip
    saengsuriya13 via Getty Images
    Image attribution tooltip

    In the renal space, innovation could tackle health disparities. But the system doesn’t reward it.

    Reimbursement challenges have created barriers for new dialysis products, according to the chief commercial officer of CorMedix.

    Michael Gibney • Sept. 14, 2023
  • Test tube blood
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    ‘We need to do better:’ A biotech CEO on standing apart from the crowd

    The CEO of Cullinan Oncology is taking a small biotech to the next step and believes the temporary financial barriers are smaller than scientific progress.

    Michael Gibney • Aug. 29, 2023
  • Rep. Adam Smith sits at a podium with blue curtain behind.
    Image attribution tooltip
    Chip Somodevilla / Staff via Getty Images
    Image attribution tooltip

    A leading Democrat reveals how his mental health struggles shape his policy approach

    Seattle Congressman Adam Smith's journey with anxiety and chronic health has influenced his perspective on healthcare and pharmaceutical policy.

    Karissa Waddick • Aug. 17, 2023
  • mrna vax
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Riding the mRNA wave, HDT Bio closes in on cancer-fighting vaccine

    The company believes its platform could deliver safer and more efficient mRNA options for cancer and infectious diseases.

    Kelly Bilodeau • Aug. 14, 2023
  • Deborah Dunsire headshot
    Image attribution tooltip
    Permission granted by Lundbeck
    Image attribution tooltip

    5 minutes with — Lundbeck CEO Dr. Deborah Dunsire

    The long-time pharma exec on her most recent wins, her favorite rule to break and the words she lives by.

    Meagan Parrish • Aug. 11, 2023
  • Michael Severino, CEO, Tessera Therapeutics
    Image attribution tooltip
    Permission granted by Tessera
    Image attribution tooltip

    Why AbbVie’s former president has high hopes for this Flagship-backed biotech

    The CEO of Tessera Therapeutics believes the company’s gene writing technology could eventually cure nearly any genetic disease across patient populations.

    Karissa Waddick • Aug. 7, 2023
  • Liver model
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    How CymaBay overcame a NASH failure for another shot at liver disease success

    The biotech’s 2019 trial halt was a major disappointment in NASH, but a turnaround has shown late-stage potential in another liver disease with unmet needs.

    Michael Gibney • Aug. 2, 2023
  • Oral contraceptive pill on pharmacy counter with colorful pills strips background.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    With OTC birth control approved, access battles have just begun

    Perrigo received the first FDA approval for an OTC birth control pill. Now, its global VP of women’s health says the company is working on the next challenge — affordability.  

    Karissa Waddick • July 26, 2023
  • loic vinent head shot
    Image attribution tooltip
    Permission granted by Affini-T Therapeutics
    Image attribution tooltip

    In fast-growing KRAS field, this oncology veteran is chasing the toughest cancer targets

    Loïc Vincent, chief scientific officer at Affini-T, explains the company’s T cell approach and latest moves toward the clinic.

    Alexandra Pecci • July 25, 2023
  • Peter Benton
    Image attribution tooltip
    Permission granted by Worldwide Clinical Trials
    Image attribution tooltip

    A leading CRO’s chief exec on why a ‘brave new world’ of clinical research is here

    Peter Benton, co-CEO of Worldwide Clinical Trials, explains how the rise of the mid-sized pharma company has changed drug R&D.  

    Taren Grom and Meagan Parrish • July 20, 2023
  • Genetic search
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Google for genes? This AI company aims to curate the entire human genome.

    Genomenon’s acquisition of their contract scientific partner Boston Genetics will help them unlock the potential of genetic knowledge. 

    Michael Gibney • July 20, 2023
  • Pharma vials
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    As biologics boom, here’s how manufacturers are keeping up

    Stevanato’s focus on biologic-related vials and delivery devices has put it in a unique position amid a quickly growing market.

    Michael Gibney • July 19, 2023
  • bullseye
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A rare disease veteran, Inozyme’s new CEO sharpens the company’s focus

    After taking the reins from the company’s founding CEO, Douglas Treco is guiding Inozyme through the clinic.

    Alexandra Pecci • July 11, 2023
  • Merck's former global headquarters in Kenilworth, New Jersey
    Image attribution tooltip
    Permission granted by Onyx Equities
    Image attribution tooltip

    Merck’s New Jersey campus is getting a biotech makeover

    With a purchase of the pharma giant’s Kenilworth campus, Onyx Equities is looking to make the spot a go-to biotech hub.

    Michael Gibney • July 11, 2023
  • Stethoscope , passport document, airplane and globe on a table.
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    A BMS exec’s journey around the world in 90 days

    As BMS grapples with upcoming patent cliffs, Emma Charles, the new SVP of intercontinental markets, is focused on expanding its footprint.

    Karissa Waddick • July 5, 2023